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Abstract
Background: Patients’ non-adherence to drug therapy is a major problem for society as it is associated with
reduced health outcomes. Generally, approximately only 50% of patients with chronic disease in developed
countries adhere to prescribed therapy, and the most common non-adherence refers to chronic under-use, i.e.
patients use less medication than prescribed or prematurely stop the therapy. Patients’ non-adherence leads to
high additional costs for society in terms of poor health. Non-adherence is also related to the unnecessary sale of
drugs. The aim of the present study was to estimate the drug acquisition cost related to non-adherence to drug
therapy in a national population.
Methods: We constructed a model of the drug acquisition cost related to non-adherence to drug therapy based on
patient register data of dispensed out-patient prescriptions in the entire Swedish population during a 12-month period.
In the model, the total drug acquisition cost was successively adjusted for the assumed different rates of primary non-
adherence (prescriptions not being filled by the patient), and secondary non-adherence (medication not being taken as
prescribed) according to the patient’s age, therapies, and the number of dispensed drugs per patient.
Results: With an assumption of a general primary non-adherence rate of 3%, and a general secondary non-
adherence rate of 50%, for all types of drugs, the acquisition cost related to non-adherence totalled SEK 11.2 billion
(€ 1.2 billion), or 48.5% of total drug acquisition costs in Sweden 2006.
With the assumption of varying primary non-adherence rates for different age groups and different secondary non-
adherence rates for varying types of drug therapies, the acquisition cost related to non-adherence totalled SEK 9.3
billion (€ 1.0 billion), or 40.2% of the total drug acquisition costs.
When the assumption of varying primary and secondary non-adherence rates for a different number of dispensed
drugs per patient was added to the model, the acquisition cost related to non-adherence totalled SEK 9.9 billion (€
1.1 billion), or 42.6% of the total drug acquisition costs.
Conclusions: Our estimate indicates that drug acquisition costs related to non-adherence represent a substantial
proportion of the economic resources in the health care sector. A low rate of primary non-adherence, combined
with a high rate of secondary non-adherence, contributes to a large degree of unnecessary medical spending.
Thus, efforts of different types of interventions are needed to improve secondary adherence.
Background
Patients’ non-adherence to drug therapy is a major pro-
blem in health care as this is associated with reduced
health outcomes [1-3]. Patients’ adherence to prescri-
bers’ drug therapy is essential for treatment efficacy,
patient safety, and healthcare costs. If patients do not
follow the prescribed drug therapy the drugs will have
no, or a reduced, effect. A large proportion of patients
in all ages with different diseases do not adhere to ther-
apy instructions. In developed countries, non-adherence
to long-term therapy for chronic diseases averages 50%
[4-6], and in developing countries the non-adherence
rate is even higher [5]. * Correspondence: bo.hovstadius@pwc.se
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non-adherence [4]: complexity of therapy [5], duration
of therapy [5], characteristics of disease [5,7], adverse
drug reactions [5,8], cost of treatment [5,7,9], character-
istics of health service provision[5], interaction between
prescriber and patient [5,10], prescribers follow-up
[5,11], multiple providers [5,10] socio-economic vari-
ables [5], multiple medication [10], the patients’ own
view of required therapy [8,12,13] and unintended non-
adherence [12]. The most common non-adherence
refers to chronic under-use, i.e. patients use less medica-
tion than prescribed, or prematurely stop the therapy
[5]. The World Health Organization (WHO) categorised
the determinants of non-adherence into five dimensions:
social and economic, health system-related, therapy-
related, condition-related, and patient-related [5].
Non-adherence is commonly divided into primary and
secondary non-adherence. Irrespective of the cause, pri-
mary non-adherence represents the prescriptions the
patient not fill at pharmacies [14,15] and secondary
non-adherence represents the dispensed drugs that the
patient not take as prescribed [15,16].
The rate of non-adherence differs between different
age groups. Generally, the rate of non-adherence
decreases with a higher age [7,8,11,12,17]. There is a
minor gender difference in non-adherence; the rate of
non-adherence is slightly higher for women than for
men [8,18,19].
Non-adherence is a problem across all therapeutic
areas [5,20,21]. However, variation in non-adherence
can, to some extent, be explained by the type of drug or
in terms of whether the patient’s drug therapy is chronic
or acute [22-25].
The use of multiple medication is a rational therapy
for many patients, but it is also a well-known risk factor
for patients’ health as multiple medication is associated
with adverse drug reactions, interactions and non-adher-
ence to drug therapy [26], and the rate of non-adher-
ence increases with an increasing number of drugs
[27-35].
Cost-related non-adherence (CRNA) is a major deter-
minant of non-adherence, [18,36]. Countries with the
lowest out-of pocket costs for drugs also have the lowest
average rate of CRNA [36]. Countries with no manda-
tory health insurance system also have large internal
variations in CRNA [9,17].
Non-adherence leads to poor health outcomes and
high extra costs for society when filled drug prescrip-
tions cannot produce an effect as they are not taken by
the patient [37]. Non-adherence also represents a waste
of substantial economic resources due to unnecessary
drug sales [16]. In the majority of countries, the cost of
wasted medication is shared between the patients and
society.
With access to the Swedish prescribed drug register, it
is possible to utilise patient-based data for an entire
national population in order to analyse drug acquisition
costs in terms of drug groups, age, gender, and multiple
medication, without any sample, recall, or interview
bias. With patient-based data on dispensed drugs, it is
possible to shift the focus from the drug exposure of the
total population, e.g. acquisition cost per inhabitant, to
the drug exposure of the patients who have actually
received different medications, e.g. acquisition cost per
patient on the basis of a certain drug.
Aim of the study
To estimate the drug acquisition costs related to non-
adherence to drug therapy in a national population.
Methods
To estimate the drug acquisition costs related to non-
adherence to drug therapy in a national population, we
studied the patient based data of all dispensed prescrip-
tion drugs in the entire Swedish population during a 12-
month period 2006. This data was extracted from the
Swedish prescribed drug register [38].
The Swedish prescribed drug register
The Swedish prescribed drug register is patient based
and contains data for dispensed out-patient prescrip-
tions at all Swedish pharmacies from July 1, 2005. The
register is complete with regard to dispensed prescrip-
tions. In 2006, dispensed out-patient prescriptions
accounted for 82% of all defined daily doses (DDD), and
the remaining 18% consisted of OTC sales and inpatient
use in hospitals [38].
The registration is mandatory and the following data
from the register was used in our study: number of
patients, the dispensed drug (substance), number of dis-
pensed prescription drugs per patient, the cost of the
drug, DDD, number of DDD per patients, the date of
dispensing, age, gender, and a unique identifier (perso-
nal identification number) of the patient.
The study population was comprised of all patients of
all ages receiving one or more dispensed drugs during
the 12-month study period that is, a total of, 6, 161, 673
(3, 481, 371 women and 2, 680, 302 men), correspond-
ing to 67.6% of the Swedish population [39].
The applied definition of drug was the chemical entity
or substance comprising the fifth level in the WHO
Anatomic, Therapeutic, Chemical (ATC) classification
2006. In the presentation, the drugs were categorized
according to the second level of the ATC-classification.
All data processing was undertaken anonymously
without the personal identification number. Only gender
and age, originally embedded in the personal identifica-
tion number, were recorded. The study population was
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results were compared to the number of individuals per
gender and age group in the Swedish population.
In Sweden, prescriptions are valid for 12 months and
the filling of one prescription usually covers consump-
tion for a 3-month period [40].
Adherence
Adherence can be defined as “the extent to which the
patient follows medical instructions” [5], or “the extent
to which patient behaviour corresponds with recom-
mendations from a health care provider” [5].
Primary and secondary adherence
Medical adherence is commonly divided into primary
adherence (prescription being filled by patient)
[14,15,41] and secondary adherence (medication used as
prescribed) [15,16,41].
Adherence measurement options include drug claims
data, interviews, surveys, pill counts and drug assays. The
majority of adherence research has addressed secondary
adherence of chronic therapies [42]. There exist a large
number of varying measurements to estimate secondary
adherence of long-term therapies from administrative
data, including e.g. MRA, MPR, and PDC [43].
A model to estimate the share of drug costs related to non-
adherence
In order to estimate the share of drug costs related to non-
adherence, we constructed a model based on the patient
data of all dispensed prescription drugs in the entire Swed-
ish population during a 12-month period, 2006. In the
model, the total drug acquisition cost was successively
adjusted for assumptions regarding different rates of pri-
mary non-adherence and secondary adherence, based on
the patient’s age, therapies, and the number of dispensed
drugs per patient. As secondary non-adherence refers to
the amount of prescribed drugs and not to the patients’
filled prescriptions, the drug cost related to non-adherence
is defined as the difference in cost between actual, filled
prescriptions (primary adherence) and a calculated estima-
tion of the total cost of the amount of drugs taken as pre-
scribed (secondary adherence).
Assumptions of non-adherence
Based on two previous studies from Sweden, we applied
a primary non-adherence rate of 3% (measured as non-
filled prescriptions at pharmacies) in the model [12,44].
The applied rate of primary non-adherence is also
equivalent to the proportion of the population which
did not fill a prescription during 2005 [18].
Gender
Generally, there is a slight gender difference in adher-
ence [8,19], but studies from Sweden have reported
contradictory results [12,18]. Thus, no gender adjust-
ment was implemented in our model.
Age
Based on previous studies [7,11,12,17,20,45], we also
adjusted our model for age difference in primary adher-
ence. The highest rate of adherence is displayed for the
elderly and children. The lowest adherence rate is dis-
played for young adults. Based on a Swedish study [18],
we applied an age primary non-adherence rate of 2% for
the age group 0-19, 4% for 20-49, 3% for 50-69, and 2%
for patients above 70.
Drug therapies
In the model, we also adjusted for differences in the
non-adherence rate between different drug therapies
[23-25]. “Short-term” drugs were categorised as the
ATC-groups in which the average DDD/patient during
the year 2006 was below 200 DDD. In the model, we
applied an assumed secondary non-adherence rate of
30% for “Short-term” drugs.
Continuing drug therapies were categorised as ATC-
groups in which the average DDD/patient during a year
was over 200 DDD. We applied an assumed secondary
non-adherence rate of 50% for continuing drug thera-
pies [4-6]. As certain drugs do not have established
DDD, we established a third category: ATC-groups with
no established DDD. We applied an assumed secondary
non-adherence rate of 30% for ATC-groups with no
established DDD.
Multiple medication
In the model, we also adjusted for differences in the sec-
ondary non-adherence rate between different numbers of
dispensed drugs per patient. Multiple medication is com-
monly associated with increasing non-adherence [26-32]
and, therefore, we assumed that the increase rate in dis-
pensed DDD per patient (primary adherence) decreases
with an increased number of prescribed drugs, as well as
with an increased rate in ingested DDD per patient (sec-
ondary adherence). Due to the lack of information on the
actual amount of prescribed drugs, the relation between
prescribed and dispensed drugs, with an increasing num-
ber of drugs, is unknown. Primary non-adherence rates
of 3-50% have been reported [8,12,46]. In our model, we
applied the following assumptions of the increasing rate
of secondary non-adherence with an increasing number
of drugs: 1 to 4 dispensed drugs (DP1-4) per patient has
a non-adherence rate of 30%, DP5-9 40%, DP10-14 50%,
and DP ≥ 15 60%.
In the result section, we excluded outliers: 7, 262
patients with more than 30 different dispensed drugs
during 2006, corresponding to 0.12% of patients with
dispensed drugs in Sweden in 2006.
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sis of data. The Regional Ethical Review Board in Lin-
köping, Sweden, approved the study. The average
exchange rate 2006 between Euro (€)a n dS v e n s kk r o n a
(SEK): 1 € = 9.25830 SEK.
Results
Total acquisition cost of dispensed drugs
The total acquisition cost of dispensed drugs in Sweden
was SEK 23.1 billion in 2006, women, SEK 12.4 and
men, SEK 10.7 billion. The average acquisition cost of
dispensed drugs per patient was SEK 3, 749, women,
SEK 3, 575 and men, SEK 3, 974 (Table 1). Patients’
total co-payment was SEK 5.8 billion or 25.2% of total
acquisition cost of dispensed drugs 2006.
Drug acquisition costs with regard to age
Patients < 60 years accounted for 50% of total drug
acquisition costs, and patients < 70 years accounted for
2 / 3o ft h et o t a ld r u ga c q u i s i t i o nc o s t s .T h ea g eg r o u p s
with the largest proportion of the total costs were 69-
69, 50-59, and 70-79 years, with 19.8, 17.2, and 17.2%,
respectively.
The average drug acquisition cost per patient
increased with an increasing age, from SEK 952 (SEK
736 for women and SEK 1, 146 for men) in the age
group 0-9, to a peak in the age group 80-89, with SEK
6, 721 (6, 378 for women and 7, 289 for men). In the
age group above 90 years, the drug acquisition cost per
patient decreased to a level comparable to the age group
60-69 years (Table 1).
Drug acquisition costs with regard to drug therapy
The 28 ATC-groups, of a total of 86, with a DDD per
patient per year above 200, were categorised as a conti-
n u i n gd r u gt h e r a p y .C o n t i n u i n gd r u gt h e r a p i e s
corresponded to 74.8% of all dispensed DDD and 59.6%
of the cost of all dispensed drugs 2006.
The 43 ATC-groups with a DDD per patient per year
below 200 were categorised as “short-term” drug ther-
apy. “Short-term” therapy ATC-groups corresponded to
25.2% of all dispensed DDD and 37.4% of the cost of all
dispensed drugs in Sweden 2006.
The remaining 15 ATC-groups have no established
DDD and corresponded to 3.0% of the total acquisition
cost of dispensed drugs.
The 7 ATC-groups with prevalence in the total popu-
lation above 10% were to be found in both continuing
and short-term drug therapies. The ATC-groups with
an acquisition cost above SEK one billion were, with
one exception, all categorised as continuing therapy.
Drug acquisition costs with regard to multiple medication
The drug acquisition costs for patients with DP ≥ 5
represented 78.8% of the total drug acquisition costs,
patients with DP ≥ 10 and DP ≥ 15, 46.3, and 23.2%,
respectively.
For patients with DP ≥ 5, DP ≥ 10, and DP ≥ 15, the
publically financed drug costs represented 80.2, 86.1,
and 89.7%, respectively (Figure 1).
The average acquisition cost per patient displayed a
near linear relationship with the numbers of dispensed
drugs per patient, from an average of SEK 527 for
patients with one drug, to SEK 37, 221 for patients with
30 different drugs, women, SEK 429 to SEK 35, 276, and
men, SEK 634 to SEK 41, 910.
Estimates of the drug acquisition costs related to non-
adherence
With an assumed primary non-adherence rate for Swe-
den of 3%, and a secondary non-adherence rate of 50%,
the drug acquisition cost related to non-adherence totals
Table 1 Number of individuals, acquisition cost, and acquisition cost per individual in Sweden 2006.
Individuals Acq cost
(* million SEK)
Acq cost/individual
Age group All Women Men All Women Men All Women Men
0-9 556, 818 263, 385 293, 433 530 194 336 952 736 1, 146
10-19 585, 481 341, 063 244, 418 1, 103 473 630 1, 884 1, 388 2, 577
20-29 650, 272 418, 256 232, 016 1, 162 667 494 1, 786 1, 596 2, 129
30-39 772, 667 456, 855 315, 812 2, 021 1, 186 834 2, 615 2, 596 2, 642
40-49 797, 753 446, 757 350, 996 2, 755 1, 514 1, 241 3, 453 3, 390 3, 534
50-59 905, 910 489, 752 416, 158 3, 983 2, 134 1, 849 4, 397 4, 358 4, 442
60-69 831, 432 436, 085 395, 347 4, 566 2, 354 2, 212 5, 492 5, 399 5, 594
70-79 598, 583 332, 601 265, 982 3, 966 2, 092 1, 874 6, 626 6, 290 7, 046
80-89 392, 433 244, 720 147, 713 2, 638 1, 561 1, 077 6, 721 6, 378 7, 289
≥ 90 70, 324 51, 897 18, 427 375 269 105 5, 326 5, 190 5, 709
Total 6, 161, 673 3, 481, 371 2, 680, 302 23, 098 12, 446 10, 651 3, 749 3, 575 3, 974
Number of individuals, acquisition cost (Acq cost), and acquisition cost per individual for all, women, and men, for different age groups in Sweden 2006.
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costs in Sweden 2006 (Table 2).
With the assumption of varying secondary non-adher-
ence rates for different types of drug therapies applied
in the model, the acquisition cost related to non-adher-
ence amounted to SEK 9, 290 million, or 40.1% of total
drug acquisition costs (Table 2).
With the assumption of varying primary non-adher-
ence rates for the different age groups applied in the
model, the acquisition cost related to non-adherence
amounted to SEK 11, 200 million, or 48.4% of total drug
acquisition costs (Table 2).
With the assumption of both different primary non-
adherence rates for different age groups, and different
secondary non-adherence rates for varying types of drug
therapies applied in the model, the acquisition costs
related to non-adherence totalled SEK 9, 268 million, or
40.0% of total drug acquisition costs (Table 2).
Finally, when assumptions of different non-adherence
rates for an increasing number of drugs were applied in
the model, the acquisition costs related to non-adher-
ence totalled SEK 9, 855 million, or 42.6% of total drug
acquisition costs (Table 3).
Discussion
There exists an “enormous amount of quantitative
research” concerning medical adherence, but there is no
golden standard for measurement [4] and studies of
medical adherence vary widely in terminology, defini-
tions and methods [47,48]. Both primary and secondary
non-adherence are problems for health care across all
therapeutic areas, but the majority of the adherence
research has referred to secondary non-adherence and
to chronic therapies [21,42]. In 2003, World Health
Organisation published “Adherence to long term thera-
pies: evidence for action”, which included specific
reviews of non-adherence in therapies for asthma, can-
cer, depression, diabetes, epilepsy, hypertension, tuber-
culosis [5]. Subsequently, comparing studies of
secondary adherence estimates for hypertension,
hyperthyroid, type 2 diabetes, seizure disorders,
hypercholesterolemia, osteoporosis, and gout [20] and
secondary adherence estimate for prostaglandin analogs,
statins, bisphosphonates, oral antidiabetics, angiotensin
II receptor blockers and overactive bladder medications
have being presented [21]. There are also a large num-
ber of specific studies and reviews of adherence for spe-
cific medical condition e.g. diabetes, hypertensions and
dyslipidaemia [49] osteoporosis [50], anticancer treat-
ment [51], HIV [52] and mental disorder [53], etc. The
reported results vary widely depending on the disease,
study setting and measurements.
As direct measurement of medication consumption is
usually not feasible, refill adherence has been applied as an
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However, when medication adherence is estimated from e.
g. pharmacy claims databases, the estimates are substan-
tially inflated as non-adherence and early non-persistent
patients are largely not included in the estimations [55].
Various studies have reported primary adherence rates of
nearly 50% in psoriasis [46], 31.4% in diabetes [14], 24.3%
in hypertension [56], and 19.9% in antidepressants [57]. In
addition, pharmacy claims databases are not feasible for
estimating the secondary adherence (medication taken as
prescribed) of “short-term” or “acute” therapies, e.g. all 11
measurements of refill adherence reported by Hess et al
are relevant only to secondary adherence for chronic/con-
tinuing therapies [43].
The basic assumptions of non-adherence
Total drug acquisition costs represent between 10-20%
of health care expenditure in developed countries [58].
The Swedish rate of 13% is the approximate average
within Europe [18]. Consequently, our results appear to
be relevant for comparison with the results from other
developed countries.
In Sweden, total drug acquisition costs show no clear
age profile. The fact that the age group 0-69 years
accounted for nearly 70% of costs indicates that the
elderly were not the most interesting age group from an
economic perspective. Drug acquisition costs per patient
increased with increasing age, and reached a peak in the
age group 70-89. Women represented somewhat more
than 50% of total drug acquisition costs, but men had a
higher average cost per patient than women in all age
groups.
Continuing drug therapies represented approximately
60% of total drug acquisition costs and were, therefore,
the dominant therapy in terms of costs related to non-
adherence. “Short-term” drug therapies represented
Table 2 Drug acquisition costs related to non-adherence with varying therapies and ages in Sweden in 2006.
Age -Therapy DDD Acq. Cost Rate of Cost of Rate of Acq. Cost related to NA
*million % million SEK % PNA prescribe drugs SNA million SEK % of Acq cost
All 5253 100 23154 100 3 23870 50 11219 48, 5
Therapy:
Continuing 3927 74, 8 13798 59, 6 3 14225 50 6686 48, 5
short-term 1326 25, 2 8659 37, 4 3 8927 30 2410 27, 8
(no DDD) 697 3, 0 3 718 30 194 27, 8
Total 5253 100 23154 100, 0 23870 9290 40, 1
Age:
0-19 241 4, 6 1641 7, 1 2 1675 50 804 49, 0
20-49 976 18, 6 5966 25, 8 4 6215 50 2859 47, 9
50-69 1894 36, 1 8568 37, 0 3 8833 50 4151 48, 5
70- 2142 40, 8 6979 30, 1 2 7122 50 3418 49, 0
Total 5253 100 23154 100, 0 239844 50 11232 48, 5
Therapy and age
Continuing
0-19 179 651 2, 8 2 664 50 319 49, 0
20-49 696 3542 15, 3 4 3689 50 1697 47, 9
50-69 1407 5267 22, 7 3 5430 50 2552 48, 5
70- 1645 4339 18, 7 2 4428 50 2125 49, 0
Short-term
0-19 63 937 4, 0 2 956 30 268 28, 6
20-49 279 2233 9, 6 4 2326 30 605 27, 1
50-69 487 2989 12, 9 3 3081 30 832 27, 8
70- 497 2501 10, 8 2 2552 30 715 28, 6
no DDD
0-19 53 0, 2 2 54 30 15 28, 6
20-49 192 0, 8 4 200 30 52 27, 1
50-69 313 1, 3 3 322 30 87 27, 8
70- 139 0, 6 2 142 30 40 28, 6
Total 5253 0 23154 100, 0 23844 9306 40, 2
DDD, acquisition costs for dispensed drug (Acq cost), rate of primary non-adherence (PNA), estimated acquisition costs for prescribed drugs, rate of secondary
non-adherence (SNA) and drug acquisition costs related to non-adherence (NA) for individuals with varying therapies and ages in Sweden in 2006.
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and had, therefore, a minor impact on total drug costs
related to non-adherence.
Multiple medication is a common cause of non-adher-
ence and the rate of non-adherence is assumed to
increase with the number of drugs per patient [27-32].
However, we have not found any studies that have
assessed, in detail, the relationship between non-adher-
ence and an increasing number of drugs. Therefore, we
made the rough assumption, that patients with a large
number of different drugs have an above average non-
adherence rate, and patients with few drugs have a
below average non-adherence rate. However, patients
with five or more drugs account for nearly 80% of total
drug acquisition costs and have, consequently, a sub-
stantial impact on total acquisition costs related to non-
adherence.
Causes of primary and secondary non-adherence
That patients do not take their medication as prescribed
(secondary non-adherence) might be due to several cir-
cumstances, e.g. the patients have experienced an
adverse drug reaction, patients do not feel that they
n e e dt h ed r u g s ,o rt h e yj u s tf o r g e tt oi n g e s tt h ed r u g s .
Secondary adherence to drug therapy also depends on
the patient’s age, gender, disease burden, the complexity
and duration of the drug therapy, as well as on the
Table 3 Drug acquisition costs related to non-adherence with different number of dispensed drugs in Sweden 2006.
DDD Acq cost PNA Prescribed SNA Cost related non-adherence
Therapy Age DP million % million % rate drug cost rate million %
Conti. 0-19 DP1-4 106 2 329 1, 4 3 339 40 126 38, 1
DP5-9 56 1, 1 224 1 2 229 50 110 49, 0
DP10-14 13 0, 2 61 0, 3 2 63 50 30 49, 0
DP15- 4 0, 1 36 0, 2 2 37 60 21 59, 2
20-49 DP1-4 273 5, 2 1151 5 4 1199 40 432 37, 5
DP5-9 236 4, 5 1301 5, 6 4 1356 50 624 47, 9
DP10-14 106 2 610 2, 6 4 636 50 292 47, 9
DP15- 81 1, 5 479 2, 1 4 499 60 279 58, 3
50-69 DP1-4 250 4, 8 855 3, 7 3 882 40 326 38, 1
DP5-9 532 10, 1 1820 7, 9 3 1876 50 882 48, 5
DP10-14 338 6, 4 1286 5, 6 3 1326 50 623 48, 5
DP15- 288 5, 5 1305 5, 6 3 1346 60 767 58, 8
70- DP1-4 118 2, 3 328 1, 4 2 335 40 127 38, 8
DP5-9 516 9, 8 1276 5, 5 2 1302 50 625 49, 0
DP10-14 525 10 1337 5, 8 2 1364 50 655 49, 0
DP15- 485 9, 2 1398 6 2 1426 60 827 59, 2
Short- 0-19 DP1-4 36 0, 7 550 2, 3 2 560 20 101 18, 3
term DP5-9 20 0, 4 263 1, 1 2 268 30 75 28, 5
DP10-14 5 0, 1 87 0, 4 2 88 40 33 38, 4
DP15- 2 0 38 0, 2 2 39 50 19 49, 3
20-49 DP1-4 97 1, 8 796 3, 4 4 830 20 133 16, 7
DP5-9 98 1, 8 764 3, 3 4 795 30 207 27, 1
DP10-14 46 0, 9 363 1, 5 4 379 40 136 37, 6
DP15- 39 0, 7 310 1, 3 4 323 50 149 47, 9
50-69 DP1-4 94 1, 8 562 2, 5 3 579 20 98 17, 5
DP5-9 169 3, 2 1000 4, 3 3 1031 30 278 27, 8
DP10-14 113 2, 2 692 2, 9 3 714 40 264 38, 2
DP15- 111 2, 2 734 3, 2 3 756 50 355 48, 4
70- DP1-4 39 0, 7 191 0, 8 2 196 20 35 18, 5
DP5-9 142 2, 8 679 2, 9 2 693 30 194 28, 6
DP10-14 155 3 763 3, 3 2 778 40 296 38, 7
DP15- 161 3 868 3, 8 2 886 50 425 49, 0
No DDD 0 0 697 3 718 50 309 44, 3
All 5254 100 23153 99, 9 23848 9855 42, 6
DDD, acquisition costs for dispensed drugs (Acq cost), rate of primary non-adherence (PNA), estimated acquisition costs for prescribed drugs, rate of secondary
non-adherence (SNA)and drug acquisition costs related to non-adherence for individuals with varying therapies, age and different number of dispensed drugs in
Sweden in 2006
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Furthermore, secondary adherence depends on whether
the prescriber follows-up therapy, if the patient feels
safe with the drugs, or has multiple providers or multi-
ple medication. Even if differences in the rate of second-
ary adherence might exist between countries, the causes
of secondary adherence are assumed to be universal.
Many characteristics of secondary adherence may also
have the subsequent effect that patients do not fill their
prescriptions (primary non-adherence).
Costs related to non-adherence
A factor which, theoretically, is exclusive to primary
adherence, is cost-related non-adherence (CRNA), and
in many countries CRNA is one of the largest determi-
nants of non-adherence. Sweden and The Netherlands
display a high rate of primary adherence compared to
most other countries [18,36]. Probably, these countries’
low CRNA rates contribute to explaining the high rates
of primary adherence. In the US, the average CRNA is
20% or more [17], but for elderly and uninsured adults,
the rate is estimated to be 30% and 40%, respectively
[7,9,17].
The low rate of CRNA in Sweden (1%) can probably
be explained by the comprehensive drug reimbursement
system. In excess of a patient co-payment ceiling of SEK
1, 800 (€195), all additional fill of prescriptions are with-
out charge. It could be expected that above this cost
ceiling, the patient have no economic incentive to
refrain from having the prescriptions filled. Due to the
perceived insistence of the health care sector, the patient
might feel that filling the prescription is the easiest thing
to do, even if the patient, for a number of reasons, does
not intend to take the medication.
The relationship between primary and secondary non-
adherence
Both primary and secondary non-adherence have, inde-
pendent of each other, an impact on the estimates of
drug acquisition costs related to non-adherence, but we
can also assume that primary non-adherence and sec-
ondary non-adherence impact each other. Without a
comprehensive drug reimbursement system, a high rate
of secondary non-adherence probably also impacts the
rate of primary non-adherence.
A low rate of primary non-adherence combined with a
high rate of secondary non-adherence leads to large
amounts of unnecessary drug costs, and a high rate of
primary non-adherence, combined with a low rate of
secondary non-adherence leads to small amounts of, or
no, unnecessary drug costs. Consequently, in order to
minimize wasteful medical spending, the difference
between primary non-adherence and secondary non-
adherence should be as limited as possible.
In a public health perspective, the largest cost for the
society is untreated diseases and not unnecessary drug
sales [59]. Interventions to increase the rate of primary
non-adherence to achieve smaller differences compared
with the rate of secondary adherence can, therefore,
comprise a sub optimising measure, if such intervention
also negatively impacts the rate of secondary non-
adherence.
The validity of the estimate of total drug acquisition costs
due to non-adherence
In our estimates, non-adherence is determined by
varying assumptions regarding the secondary non-
adherence rate for age, therapy, and multiple medica-
tion. The main determinant is the non-adherence rate
of different therapies. However, the proportion of
costs referring to non-adherence is approximately 40%
of total drug acquisition costs, largely irrespective of
any change in the basic assumptions in terms of the
non-adherence rate of different therapies. An assumed
higher secondary non-adherence rate for “short-term”
drug therapies (from 30% to 40%) results in a minor
increase in total costs related to non-adherence (from
40 to 44%). If, at the same time, the threshold value
for continuing drug therapy is raised (from 200 to 300
DDD per patient per year), total costs related to non-
adherence, instead, increase marginally (from 40 to
41%).
The most common non-adherence is for chronic
under-use, i.e. patients use less medication than pre-
scribed, or prematurely stop therapy [5], and therefore,
we have assumed that the volume of drugs within the
non-adherence has no effect on health outcomes. How-
ever, it could be assumed that certain amounts of the
ingested drugs, but which are not taken in full according
to the prescription or recommendation might have some
positive effect on the health outcome. This assumption
will not change the estimate of drug acquisition costs
related to non-adherence, but can be seen as an argu-
ment that the definition of non-adherence to drug
therapies might overestimate the volume of unnecessary
drug sales.
The relevance of total drug acquisition costs due to non-
adherence
That patients’ non-adherence to therapy leads to high
extra costs for society in terms of poor health for
patients [37], and to the fact that as approximately 40%
of the total drug acquisition costs is related to patients’
non-adherence to drug therapies, this must be seen to
c o m p r i s eah i g h l yn o n - s a t i s f a c t o r ys i t u a t i o n .A st h e
amount of total drug acquisition costs represented
approximately a third of the total cost of primary care
in Sweden in 2006 [60], this should also be considered
by the health care stakeholders as being highly relevant
in an economic perspective.
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Non-adherence to drug therapies represents a waste of
large amounts of economic resources, both for the
patients and for society. A reduction of drug acquisition
costs related to non-adherence should be achieved by
interventions focused on improving secondary adher-
ence, e.g. active handling to change patient behaviour,
reduce side effects and therapy complexity, improving
the provision of health services, and improving the
interaction between health care personnel and patients.
Interventions should be directed to patients or to pro-
viders, or health care managers. Sadly, long term
patient-focused intervention has shown to have no sub-
stantial effect on adherence [5], e.g. attempts with differ-
ent types of patient reminding-systems for filling of
prescriptions have shown no significant effects [61-63],
but the routine follow-up by the prescriber has dis-
played significant increasing adherence [11,64]. An
intervention directed to prescribers to decrease the com-
plexity of the drug therapy, e.g. a change to one dosage
a day instead of two, has also improved adherence [5].
Another intervention that have been suggested is the
introduction of financial incentives or other rewards for
patients who adhere to therapy [65].
A low rate of primary non-adherence not combined
with a low rate of secondary non-adherence results in
major costs for patients and society in terms of unneces-
sary drug sales. A reduction of the cost related to non-
adherence can, therefore, also be achieved by interven-
tions aimed at increasing primary non-adherence, e.g.
modifying the drug reimbursement system to better cor-
respond with patients’ secondary non-adherence.
Strengths and limitations
The study is based on patient data on pharmacy claims
without any sample, recall or interview bias for all
patients with dispensed drugs in an entire national
population. The study combined actual pharmacy
claims data with general assumptions based on pre-
vious studies of different non-adherence rates for
patients in different age groups, drug therapies, and
with a varying number of dispensed drugs. A limitation
is that the assumptions made in the present study are
based on previous studies that often only focus on
adherence to one specific long-term medical therapy.
Results from previous studies concerning the non-
adherence rate for short-term therapies, patients’ age,
and number of dispensed drugs per patient are often
only qualitative. Consequently, certain of the assump-
tions about varying non-adherence rates in the present
study are relatively rough. Furthermore, the register
includes all dispensed prescriptions drugs but has no
information regarding other types of drugs e.g. OTC-
drugs and CAM. Nor has the register any information
about the volume and the distribution of prescribed
drugs that are not filled, nor as regards the rate of
filled drug not taken as prescribed
Conclusions
Our estimate indicates that drug acquisition costs
related to non-adherence represent a substantial propor-
tion of the economic resources in the health care sector.
A low rate of primary non-adherence, combined with a
high rate of secondary non-adherence, contributes to a
large amount of unnecessary medical spending. Thus,
efforts of different types of interventions are needed to
improve secondary adherence.
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